Related Experiment Video

Updated: Oct 22, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose-response model

Satyawan B Jadhav1, Ryan L Crass1, Sunny Chapel1

  • 1Ann Arbor Pharmacometrics Group, 900 Victors Way #328, Ann Arbor, MI 48108, USA.

European Heart Journal. Cardiovascular Pharmacotherapy
|August 27, 2021
PubMed

Insights

Bempedoic acid combined with lower statin doses achieves similar LDL-C reduction as higher statin doses alone. This combination may reduce adverse events for patients needing additional lipid-lowering therapy.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Lipid Metabolism

Background:

  • Many patients fail to reach guideline-recommended LDL cholesterol (LDL-C) targets even with maximal statin therapy.
  • Bempedoic acid effectively lowers LDL-C, with or without statins.

Purpose of the Study:

  • To develop a dose-response model for predicting LDL-C pharmacodynamics of bempedoic acid and statin combinations.
  • To evaluate the efficacy of combining bempedoic acid with various statin doses.

Main Methods:

  • Pooled data from 14 Phase 1-3 clinical studies involving bempedoic acid and statin dosing.
  • Developed dose-response models for bempedoic acid monotherapy and in combination with statins.
  • Simulated LDL-C changes with bempedoic acid plus atorvastatin, rosuvastatin, simvastatin, and pravastatin.

Main Results:

  • Models predicted that combining bempedoic acid with low-dose statins yielded similar LDL-C lowering as high-dose statin monotherapy.
  • Example: Atorvastatin 20 mg + bempedoic acid 180 mg predicted 54% LDL-C lowering, comparable to atorvastatin 80 mg.
  • Example: Simvastatin 10 mg + bempedoic acid 180 mg predicted 46% LDL-C lowering, similar to simvastatin 40 mg.

Conclusions:

  • Bempedoic acid combined with lower statin doses offers comparable LDL-C reduction to higher-dose statin monotherapy.
  • This combination may mitigate adverse events associated with high-dose statins in patients requiring intensified lipid-lowering therapy.
Abstract

Keywords:
Dose responseDrug interactionHypercholesterolaemiaLDL cholesterolStatin

More Related Videos

Diagonal Method to Measure Synergy Among Any Number of Drugs12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.0K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.4K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
37
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
118
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
4.2K
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
38
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
350
Time Course of Drug Effect01:14

Time Course of Drug Effect

The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.3K